The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …

The SARS-CoV-2 pandemic has led to an urgent need to understand the molecular basis for
immune recognition of SARS-CoV-2 spike (S) glycoprotein antigenic sites. To define the …

Mutations in the spike glycoproteins of SARS-CoV-2 variants of concern have independently
been shown to enhance aspects of spike protein fitness. Here, we describe an antibody …

Many individuals mount nearly identical antibody responses to SARS-CoV-2. To gain insight
into how the viral spike (S) protein receptor-binding domain (RBD) might evolve in response …

Understanding SARS-CoV-2 evolution and host immunity is critical to control COVID-19
pandemics. At the core is an arms-race between SARS-CoV-2 antibody and angiotensin …

The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for
many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under …

Mutations and transient conformational movements of the receptor binding domain (RBD)
that make neutralizing epitopes momentarily unavailable present immune escape routes for …

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Responsible for more than 4.9 million deaths so far, COVID-19, caused by SARS-CoV-2, is
instigating devastating effects on the global health care system whose impacts could be …

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has
been spreading rampantly. The global scientific community has responded rapidly to …